HUE046454T2 - Retinitis pigmentosa génterápia - Google Patents

Retinitis pigmentosa génterápia

Info

Publication number: HUE046454T2
Authority: HU; Hungary
Prior art keywords: gene therapy; retinitis pigmentosa; pigmentosa; retinitis; therapy
Prior art date: 2014-03-21

Application number

HUE15716232A

Other languages

English (en)

Inventor

Catherine O'riordan

Matthew Adamowicz

Original Assignee

Genzyme Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-21

Filing date

2015-03-20

Publication date

2020-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE046454(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-20 Application filed by Genzyme Corp filed Critical Genzyme Corp

2020-03-30 Publication of HUE046454T2 publication Critical patent/HUE046454T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/34—Allele or polymorphism specific uses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Ophthalmology & Optometry (AREA)
Virology (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Marine Sciences & Fisheries (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Dermatology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HUE15716232A 2014-03-21 2015-03-20 Retinitis pigmentosa génterápia HUE046454T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461969027P	2014-03-21	2014-03-21

Publications (1)

Publication Number	Publication Date
HUE046454T2 true HUE046454T2 (hu)	2020-03-30

Family

ID=52829343

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
HUE15716232A HUE046454T2 (hu)	2014-03-21	2015-03-20	Retinitis pigmentosa génterápia
HUE19186929A HUE063460T2 (hu)	2014-03-21	2015-03-20	Retinitis pigmentosa génterápia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
HUE19186929A HUE063460T2 (hu)	2014-03-21	2015-03-20	Retinitis pigmentosa génterápia

Country Status (36)

Country	Link
US (3)	US10383953B2 (hu)
EP (3)	EP3628334B1 (hu)
JP (3)	JP6669664B2 (hu)
KR (2)	KR20230006039A (hu)
CN (2)	CN106456660B (hu)
AR (1)	AR099837A1 (hu)
AU (3)	AU2015230942B2 (hu)
CA (1)	CA2943185A1 (hu)
CL (1)	CL2016002333A1 (hu)
CR (1)	CR20160480A (hu)
DK (2)	DK3628334T5 (hu)
DO (1)	DOP2016000237A (hu)
EA (1)	EA201691891A1 (hu)
EC (1)	ECSP16083000A (hu)
ES (2)	ES2957840T3 (hu)
FI (1)	FI3628334T3 (hu)
HR (2)	HRP20231077T1 (hu)
HU (2)	HUE046454T2 (hu)
IL (3)	IL247543B (hu)
LT (2)	LT3628334T (hu)
MA (1)	MA39390B2 (hu)
MX (2)	MX376190B (hu)
MY (1)	MY190726A (hu)
NZ (1)	NZ724622A (hu)
PE (1)	PE20161252A1 (hu)
PH (1)	PH12016501684B1 (hu)
PL (2)	PL3119437T3 (hu)
PT (2)	PT3628334T (hu)
RS (2)	RS64611B1 (hu)
SG (3)	SG11201607005UA (hu)
SI (2)	SI3628334T1 (hu)
TW (2)	TWI780401B (hu)
UA (1)	UA120050C2 (hu)
UY (1)	UY36044A (hu)
WO (1)	WO2015143418A2 (hu)
ZA (1)	ZA201605924B (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3628334B1 (en)	2014-03-21	2023-06-28	Genzyme Corporation	Gene therapy for retinitis pigmentosa
US10450563B2 (en)	2015-02-10	2019-10-22	Genzyme Corporation	Variant RNAi
US11059871B2 (en)	2015-12-03	2021-07-13	Friedrich Miescher Institute For Biomedical Research	SYNP162, a promoter for the specific expression of genes in rod photoreceptors
CN108474001B (zh) *	2015-12-03	2022-04-08	弗里德里克·米谢尔生物医学研究所	SynP160，用于基因在视杆光感受器中特异性表达的启动子
KR102312253B1 (ko) *	2015-12-04	2021-10-15	쏘흐본느 유니베흐시테	프로모터 및 이의 용도
US11118185B2 (en) *	2016-03-01	2021-09-14	University Of Florida Research Foundation, Incorporated	AAV vectors for treatment of dominant retinitis pigmentosa
AU2017293773A1 (en) *	2016-07-05	2019-02-21	The Johns Hopkins University	CRISPR/Cas9-based compositions and methods for treating retinal degenerations
CA3056211A1 (en) *	2017-03-21	2018-09-27	Stylianos MICHALAKIS	Gene therapy for the treatment of cngb1-linked retinitis pigmentosa
MY205041A (en) *	2017-09-22	2024-09-29	Genzyme Corp	Variant rnai
US20200263196A1 (en) *	2017-09-27	2020-08-20	Sigilon Therapeutics, Inc.	Methods, compositions, and implantable elements comprising active cells
CN107961380B (zh) *	2017-11-23	2020-05-05	清华大学	试剂在制备药物中的用途、筛选药物的方法以及药物组合物
WO2019169245A1 (en)	2018-03-02	2019-09-06	Sigilon Therapeutics, Inc.	Biocompatible hydrogel capsules and process for preparing same
JP2021519067A (ja) *	2018-03-23	2021-08-10	ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク	常染色体優性疾患のための遺伝子編集
IL312315A (en)	2018-04-04	2024-06-01	Sigilon Therapeutics Inc	Implantable particles and related methods
US12203074B2 (en)	2018-06-01	2025-01-21	University Of Florida Research Foundation, Incorporated	Compositions and methods for treatment of dominant retinitis pigmentosa
GB201817469D0 (en) *	2018-10-26	2018-12-12	Univ Oxford Innovation Ltd	Gene therapy for retinal disease
CN111518813B (zh) *	2019-02-03	2023-04-28	武汉纽福斯生物科技有限公司	视紫红质的编码序列、其表达载体构建及其应用
JP7637060B2 (ja) *	2019-03-04	2025-02-27	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	Ａｋｔ経路を標的とする神経保護遺伝子療法
EP3941530A4 (en) *	2019-03-21	2022-12-14	PTC Therapeutics, Inc.	VECTOR AND METHOD FOR TREATING ANGELMAN SYNDROME
BR112022002794A2 (pt) *	2019-08-15	2022-08-09	Childrens Hospital Philadelphia	Terapia combinada de transgene e mirna derivado de íntron para tratamento de sca1
KR102396200B1 (ko) *	2020-07-24	2022-05-12	알지노믹스 주식회사	로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도
EP4323390A1 (en) *	2021-04-16	2024-02-21	Regeneron Pharmaceuticals, Inc.	Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) *	2022-11-02	2024-02-11	慈濟學校財團法人慈濟大學	Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
CN117625619B (zh) *	2023-12-05	2024-11-12	云舟生物科技(广州)股份有限公司	核酸分子及其作为特异启动子的应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5262529A (en) *	1990-01-24	1993-11-16	President And Fellows Of Harvard College	Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) *	1992-06-23	1999-11-16	Mount Sinai School Of Medicine Of The City University Of New York	Cloning and expression of gonadotropin-releasing hormone receptor
US6989264B2 (en)	1997-09-05	2006-01-24	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en)	1997-09-05	2003-05-20	Targeted Genetics Corporation	Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6596535B1 (en)	1999-08-09	2003-07-22	Targeted Genetics Corporation	Metabolically activated recombinant viral vectors and methods for the preparation and use
JP4860886B2 (ja)	2000-06-01	2012-01-25	ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル	二本鎖パルボウイルスベクター
HU230406B1 (hu)	2001-11-13	2016-04-28	The Trustees Of The University Of Pennsylvania	Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására és az azzal azonosított új szekvenciák izolálására
EP1486567A1 (en)	2003-06-11	2004-12-15	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Improved adeno-associated virus (AAV) vector for gene therapy
CA2553976C (en) *	2004-01-22	2013-09-24	Dnavec Research Inc.	Method for producing minus-strand rna viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken .beta.-actin promoter
US7765583B2 (en)	2005-02-28	2010-07-27	France Telecom	System and method for managing virtual user domains
US8283151B2 (en)	2005-04-29	2012-10-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
EP2007795B1 (en)	2006-03-30	2016-11-16	The Board Of Trustees Of The Leland Stanford Junior University	Aav capsid proteins
CA2683469C (en) *	2007-04-12	2019-11-26	The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth	Genetic suppression and replacement
US20090214478A1 (en)	2008-02-21	2009-08-27	Alberto Auricchio	Method of treating ocular diseases by gene therapy
US9217155B2 (en) *	2008-05-28	2015-12-22	University Of Massachusetts	Isolation of novel AAV'S and uses thereof
US8734809B2 (en) *	2009-05-28	2014-05-27	University Of Massachusetts	AAV's and uses thereof
US9078914B2 (en)	2009-09-10	2015-07-14	Velin-Pharma A/S	Method for the preparation of micro-RNA and its therapeutic application
IN2012DN06629A (hu) *	2010-01-28	2015-10-23	Philadelphia Children Hospital
US8663624B2 (en)	2010-10-06	2014-03-04	The Regents Of The University Of California	Adeno-associated virus virions with variant capsid and methods of use thereof
WO2012057363A1 (ja)	2010-10-27	2012-05-03	学校法人自治医科大学	神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
SG10201601110VA (en)	2011-02-17	2016-03-30	Univ Pennsylvania	Compositions and methods for altering tissue specificity and improving aav9-mediated gene transfer
JP5884152B2 (ja)	2011-07-29	2016-03-15	シャープ株式会社	基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) *	2011-12-23	2013-06-24	Internat Ct For Genetic En Gineering And	Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
SG11201404956PA (en) *	2012-02-17	2014-09-26	Philadelphia Children Hospital	Aav vector compositions and methods for gene transfer to cells, organs and tissues
CA2868393A1 (en) *	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9127274B2 (en) *	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
LT2800811T (lt)	2012-05-25	2017-09-11	The Regents Of The University Of California	Būdai ir kompozicijos, skirti tikslinės dnr modifikavimui, panaudojant adresuotą rnr, ir transkripcijos moduliavimui, panaudojant adresuotą rnr
CN105120901A (zh) *	2012-07-11	2015-12-02	宾夕法尼亚大学托管会	Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
WO2014066498A1 (en) *	2012-10-23	2014-05-01	Vivek Mittal	Treatment of metastatic breast cancer
CN105792852B (zh)	2013-10-04	2019-12-10	默沙东公司	葡萄糖响应性的胰岛素缀合物
EP3628334B1 (en)	2014-03-21	2023-06-28	Genzyme Corporation	Gene therapy for retinitis pigmentosa

2015
- 2015-03-20 EP EP19186929.6A patent/EP3628334B1/en active Active
- 2015-03-20 MY MYPI2016703077A patent/MY190726A/en unknown
- 2015-03-20 ES ES19186929T patent/ES2957840T3/es active Active
- 2015-03-20 MA MA39390A patent/MA39390B2/fr unknown
- 2015-03-20 SI SI201531966T patent/SI3628334T1/sl unknown
- 2015-03-20 SG SG11201607005UA patent/SG11201607005UA/en unknown
- 2015-03-20 PT PT191869296T patent/PT3628334T/pt unknown
- 2015-03-20 RS RS20230833A patent/RS64611B1/sr unknown
- 2015-03-20 SG SG10201912968WA patent/SG10201912968WA/en unknown
- 2015-03-20 RS RS20191551A patent/RS59634B1/sr unknown
- 2015-03-20 PE PE2016001643A patent/PE20161252A1/es unknown
- 2015-03-20 ES ES15716232T patent/ES2760263T3/es active Active
- 2015-03-20 LT LTEP19186929.6T patent/LT3628334T/lt unknown
- 2015-03-20 MX MX2016012201A patent/MX376190B/es active IP Right Grant
- 2015-03-20 NZ NZ724622A patent/NZ724622A/en unknown
- 2015-03-20 HU HUE15716232A patent/HUE046454T2/hu unknown
- 2015-03-20 SG SG10201808218YA patent/SG10201808218YA/en unknown
- 2015-03-20 LT LTEP15716232.2T patent/LT3119437T/lt unknown
- 2015-03-20 US US15/127,757 patent/US10383953B2/en active Active
- 2015-03-20 AU AU2015230942A patent/AU2015230942B2/en active Active
- 2015-03-20 EP EP23176679.1A patent/EP4345165A3/en active Pending
- 2015-03-20 CR CR20160480A patent/CR20160480A/es unknown
- 2015-03-20 CA CA2943185A patent/CA2943185A1/en active Pending
- 2015-03-20 HR HRP20231077TT patent/HRP20231077T1/hr unknown
- 2015-03-20 SI SI201531019T patent/SI3119437T1/sl unknown
- 2015-03-20 JP JP2016557218A patent/JP6669664B2/ja active Active
- 2015-03-20 FI FIEP19186929.6T patent/FI3628334T3/fi active
- 2015-03-20 DK DK19186929.6T patent/DK3628334T5/da active
- 2015-03-20 CN CN201580026274.0A patent/CN106456660B/zh active Active
- 2015-03-20 WO PCT/US2015/021896 patent/WO2015143418A2/en not_active Application Discontinuation
- 2015-03-20 EP EP15716232.2A patent/EP3119437B1/en active Active
- 2015-03-20 KR KR1020227045369A patent/KR20230006039A/ko not_active Ceased
- 2015-03-20 HR HRP20192141TT patent/HRP20192141T1/hr unknown
- 2015-03-20 HU HUE19186929A patent/HUE063460T2/hu unknown
- 2015-03-20 DK DK15716232T patent/DK3119437T3/da active
- 2015-03-20 UA UAA201610589A patent/UA120050C2/uk unknown
- 2015-03-20 PT PT157162322T patent/PT3119437T/pt unknown
- 2015-03-20 EA EA201691891A patent/EA201691891A1/ru unknown
- 2015-03-20 CN CN202210690697.4A patent/CN115252823A/zh active Pending
- 2015-03-20 KR KR1020167028893A patent/KR20160127832A/ko not_active Ceased
- 2015-03-20 PL PL15716232T patent/PL3119437T3/pl unknown
- 2015-03-20 PL PL19186929.6T patent/PL3628334T3/pl unknown
- 2015-03-23 UY UY0001036044A patent/UY36044A/es not_active Application Discontinuation
- 2015-03-23 TW TW109103078A patent/TWI780401B/zh active
- 2015-03-23 TW TW104109152A patent/TWI706789B/zh active
- 2015-03-25 AR ARP150100879A patent/AR099837A1/es active IP Right Grant
2016
- 2016-08-24 PH PH1/2016/501684A patent/PH12016501684B1/en unknown
- 2016-08-25 ZA ZA2016/05924A patent/ZA201605924B/en unknown
- 2016-08-30 IL IL247543A patent/IL247543B/en active IP Right Grant
- 2016-09-09 DO DO2016000237A patent/DOP2016000237A/es unknown
- 2016-09-15 CL CL2016002333A patent/CL2016002333A1/es unknown
- 2016-09-20 MX MX2020010694A patent/MX2020010694A/es unknown
- 2016-10-21 EC ECIEPI201683000A patent/ECSP16083000A/es unknown
2019
- 2019-07-03 US US16/503,091 patent/US11103598B2/en active Active
- 2019-12-12 JP JP2019224202A patent/JP7048563B2/ja active Active
2020
- 2020-07-08 IL IL275918A patent/IL275918B/en unknown
2021
- 2021-02-15 AU AU2021200988A patent/AU2021200988B2/en active Active
- 2021-07-11 IL IL284741A patent/IL284741B2/en unknown
- 2021-07-22 US US17/383,052 patent/US12201698B2/en active Active
2022
- 2022-03-23 JP JP2022046280A patent/JP7534348B2/ja active Active
2024
- 2024-10-30 AU AU2024227776A patent/AU2024227776A1/en active Pending

Also Published As

Publication number	Publication date
AR099837A1 (es)	2016-08-24
EA201691891A1 (ru)	2017-01-30
TWI706789B (zh)	2020-10-11
PH12016501684B1 (en)	2023-03-17
TW201622752A (zh)	2016-07-01
JP7048563B2 (ja)	2022-04-05
JP2022084810A (ja)	2022-06-07
US20200046851A1 (en)	2020-02-13
MX2016012201A (es)	2017-01-19
MX376190B (es)	2025-03-07
SG10201912968WA (en)	2020-02-27
PT3119437T (pt)	2019-12-12
TWI780401B (zh)	2022-10-11
DK3628334T3 (da)	2023-10-02
DK3628334T5 (da)	2024-09-02
US11103598B2 (en)	2021-08-31
AU2021200988A1 (en)	2021-03-11
US10383953B2 (en)	2019-08-20
SG10201808218YA (en)	2018-10-30
BR112016021017A2 (pt)	2017-10-03
HRP20192141T1 (hr)	2020-02-21
JP2020059737A (ja)	2020-04-16
PL3628334T3 (pl)	2023-12-18
LT3119437T (lt)	2019-12-27
RS59634B1 (sr)	2020-01-31
DK3119437T3 (da)	2019-12-09
CN106456660A (zh)	2017-02-22
EP3119437B1 (en)	2019-09-04
SG11201607005UA (en)	2016-09-29
UA120050C2 (uk)	2019-09-25
IL275918A (en)	2020-08-31
EP3119437A2 (en)	2017-01-25
PE20161252A1 (es)	2016-11-30
AU2024227776A1 (en)	2024-11-28
CN106456660B (zh)	2022-05-31
ECSP16083000A (es)	2017-02-24
SI3119437T1 (sl)	2020-01-31
UY36044A (es)	2015-10-30
IL284741B (en)	2022-10-01
NZ724622A (en)	2022-05-27
PL3119437T3 (pl)	2020-04-30
MY190726A (en)	2022-05-12
KR20160127832A (ko)	2016-11-04
ES2760263T3 (es)	2020-05-13
IL247543A0 (en)	2016-11-30
EP3628334A1 (en)	2020-04-01
IL284741A (en)	2021-08-31
AU2015230942A1 (en)	2016-10-13
AU2021200988B2 (en)	2024-08-01
MA39390B2 (fr)	2022-04-29
HUE063460T2 (hu)	2024-01-28
SI3628334T1 (sl)	2023-11-30
US20170173183A1 (en)	2017-06-22
WO2015143418A2 (en)	2015-09-24
EP4345165A3 (en)	2024-09-25
HRP20231077T1 (hr)	2023-12-22
IL284741B2 (en)	2023-02-01
AU2015230942B2 (en)	2020-11-19
IL275918B (en)	2021-07-29
KR20230006039A (ko)	2023-01-10
MX2020010694A (es)	2020-11-06
JP2017509632A (ja)	2017-04-06
FI3628334T3 (fi)	2023-09-15
CR20160480A (es)	2016-12-14
ES2957840T3 (es)	2024-01-26
CA2943185A1 (en)	2015-09-24
PH12016501684A1 (en)	2016-10-03
IL247543B (en)	2020-07-30
PT3628334T (pt)	2023-09-26
MA39390A1 (fr)	2017-12-29
ZA201605924B (en)	2017-09-27
CN115252823A (zh)	2022-11-01
EP4345165A2 (en)	2024-04-03
US20220054657A1 (en)	2022-02-24
WO2015143418A3 (en)	2015-11-19
US12201698B2 (en)	2025-01-21
RS64611B1 (sr)	2023-10-31
JP6669664B2 (ja)	2020-03-18
EP3628334B1 (en)	2023-06-28
CL2016002333A1 (es)	2017-05-26
TW202021627A (zh)	2020-06-16
JP7534348B2 (ja)	2024-08-14
DOP2016000237A (es)	2016-10-16
NZ762841A (en)	2023-11-24
LT3628334T (lt)	2023-09-25